Price Don’t Lie: Can Emergent Biosolutions Inc’s Tomorrow Be Different? The Stock Increases Again

Price Don't Lie: Can Emergent Biosolutions Inc's Tomorrow Be Different? The Stock Increases Again

The stock of Emergent Biosolutions Inc (NYSE:EBS) is a huge mover today! About 1.14M shares traded hands or 169.54% up from the average. Emergent Biosolutions Inc (NYSE:EBS) has declined 22.76% since February 26, 2016 and is downtrending. It has underperformed by 33.18% the S&P500.
The move comes after 7 months positive chart setup for the $1.22 billion company. It was reported on Sep, 30 by We have $38.84 PT which if reached, will make NYSE:EBS worth $280.60 million more.

Analysts await Emergent Biosolutions Inc (NYSE:EBS) to report earnings on November, 3. They expect $0.42 EPS, down 49.40% or $0.41 from last year’s $0.83 per share. EBS’s profit will be $16.23M for 18.80 P/E if the $0.42 EPS becomes a reality. After $-0.18 actual EPS reported by Emergent Biosolutions Inc for the previous quarter, Wall Street now forecasts -333.33% EPS growth.

Emergent Biosolutions Inc (NYSE:EBS) Ratings Coverage

Out of 3 analysts covering Emergent Biosolutions (NYSE:EBS), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Emergent Biosolutions has been the topic of 5 analyst reports since August 10, 2015 according to StockzIntelligence Inc. The stock has “Outperform” rating given by Wells Fargo on Friday, February 19. The rating was initiated by Singular Research on Monday, March 28 with “Buy”. On Monday, August 10 the stock rating was upgraded by Zacks to “Hold”. The stock has “Buy” rating given by Singular Research on Tuesday, June 28. The stock has “Buy” rating given by Chardan Capital Markets on Friday, April 15.

According to Zacks Investment Research, “EMERGENT BIOSULUTIONS INC. is a leading biopharmaceutical company dedicated to one simple mission – to protect life. EBS develops, manufactures and commercializes vaccines and therapeutics that assist the body’s immune system to prevent or treat disease. Their products target infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs. Their marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection.”

Insitutional Activity: The institutional sentiment increased to 1.56 in 2016 Q2. Its up 0.33, from 1.23 in 2016Q1. The ratio is positive, as 25 funds sold all Emergent Biosolutions Inc shares owned while 55 reduced positions. 35 funds bought stakes while 90 increased positions. They now own 35.17 million shares or 5.50% more from 33.34 million shares in 2016Q1.
Millennium Mngmt Ltd Liability Company has 148,718 shares for 0.01% of their US portfolio. Mackenzie Fincl holds 0% of its portfolio in Emergent Biosolutions Inc (NYSE:EBS) for 27,342 shares. Paloma Prtnrs has 0.01% invested in the company for 37,975 shares. Acadian Asset Mngmt Lc holds 1.59M shares or 0.23% of its portfolio. Moreover, Bogle Mngmt L P De has 0.56% invested in Emergent Biosolutions Inc (NYSE:EBS) for 287,766 shares. Tower Rech Cap Ltd (Trc) owns 4 shares or 0% of their US portfolio. State Of Tennessee Treasury Department has 24,170 shares for 0% of their US portfolio. Aberdeen Asset Mgmt Public Ltd Company Uk holds 725,018 shares or 0.08% of its portfolio. Louisiana State Employees Retirement Sys accumulated 13,800 shares or 0.02% of the stock. Arbor Mgmt Ltd Com accumulated 1.38% or 93,000 shares. Gemmer Asset Management Limited Co accumulated 0% or 23 shares. Spark Inv Mgmt Lc holds 0.39% of its portfolio in Emergent Biosolutions Inc (NYSE:EBS) for 148,800 shares. Sawgrass Asset Mgmt Limited Co has 0.03% invested in the company for 19,870 shares. Mycio Wealth Partners Ltd Llc has 0% invested in the company for 500 shares. Panagora Asset Mngmt Inc has 0.02% invested in the company for 137,069 shares.

Insider Transactions: Since April 1, 2016, the stock had 0 insider buys, and 15 insider sales for $14.83 million net activity. Hauer Jerome M had sold 3,134 shares worth $129,183. $207,364 worth of Emergent Biosolutions Inc (NYSE:EBS) was sold by JOULWAN GEORGE A on Monday, June 6. El-Hibri Fuad also sold $1.95 million worth of Emergent Biosolutions Inc (NYSE:EBS) on Wednesday, April 6. The insider Abdun-Nabi Daniel sold 8,699 shares worth $380,494. 43,572 shares were sold by Kramer Robert, worth $1.55M on Friday, April 1. 27,867 shares were sold by Harsanyi Zsolt, worth $1.18M on Tuesday, May 24. On Thursday, May 12 the insider SULLIVAN LOUIS W sold $1.87M.

More notable recent Emergent Biosolutions Inc (NYSE:EBS) news were published by: which released: “Emergent BioSolutions Is Oversold” on June 27, 2016, also with their article: “Emergent Biosolutions Shares Up 13% on Heavy Volume; Co. Earlier Offered …” published on September 30, 2016, published: “Why Emergent BioSolutions Inc. Procured a Lower Price Today” on June 22, 2016. More interesting news about Emergent Biosolutions Inc (NYSE:EBS) were released by: and their article: “Emergent BioSolutions Inc. Asks for Patience” published on August 11, 2016 as well as‘s news article titled: “Emergent BioSolutions Inc. Expanding Along” with publication date: March 07, 2016.

EBS Company Profile

Emergent BioSolutions Inc., incorporated on December 19, 2003, is a biopharmaceutical firm that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Firm develops, makes and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID). It also develops and commercializes therapeutics, and other specialty products for hospitals and clinics in the areas of hematology/oncology, transplantation, infectious diseases and autoimmune disorders. The Company’s two operating divisions include Biodefense and Biosciences.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment